Maintenance of cardiac energy by histone deacetylase 3 metabolism in mice

被引:295
作者
Montgomery, Rusty L. [1 ]
Potthoff, Matthew J. [1 ]
Haberland, Michael [1 ]
Qi, Xiaoxia [1 ]
Matsuzaki, Satoshi [2 ]
Humphries, Kenneth M. [2 ]
Richardson, James A. [1 ,3 ]
Bassel-Duby, Rhonda [1 ]
Olson, Eric N. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA
[2] Oklahoma Med Res Fdn, Free Radical Biol & Aging Res Program, Oklahoma City, OK 73104 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA
关键词
D O I
10.1172/JCI35847
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Histone deacetylase (HDAC) inhibitors show remarkable therapeutic potential for a variety of disorders, including cancer, neurological disease, and cardiac hypertrophy. However, the specific HDAC isoforms that mediate their actions are unclear, as are the physiological and pathological functions of individual HDACs in vivo. To explore the role of Hdac3 in the heart, we generated mice with a conditional Hdac3 null allele. Although global deletion of Hdac3 resulted in lethality by E9.5, mice with a cardiac-specific deletion of Hdac3 survived until 3-4 months of age. At this time, they showed massive cardiac hypertrophy and upregulation of genes associated with fatty acid uptake, fatty acid oxidation, and electron transport/oxidative phosphorylation accompanied by fatty acid-induced myocardial lipid accumulation and elevated triglyceride levels. These abnormalities in cardiac metabolism can be attributed to excessive activity of the nuclear receptor PPAR alpha. The phenotype associated with cardiac-specific Hdac3 gene deletion differs from that of all other Hdac gene mutations. These findings reveal a unique role for Hdac3 in maintenance of cardiac function and regulation of myocardial energy metabolism.
引用
收藏
页码:3588 / 3597
页数:10
相关论文
共 51 条
[1]   Gene recombination in postmitotic cells - Targeted expression of cre recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo [J].
Agah, R ;
Frenkel, PA ;
French, BA ;
Michael, LH ;
Overbeek, PA ;
Schneider, MD .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (01) :169-179
[2]   Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors [J].
Antos, CL ;
McKinsey, TA ;
Dreitz, M ;
Hollingsworth, LM ;
Zhang, CL ;
Schreiber, K ;
Rindt, H ;
Gorczynski, RJ ;
Olson, EN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (31) :28930-28937
[3]   Diabetic cardiomyopathy revisited [J].
Boudina, Sihem ;
Abel, E. Dale .
CIRCULATION, 2007, 115 (25) :3213-3223
[4]   Mitochondrial uncoupling: A key contributor to reduced cardiac efficiency in diabetes [J].
Boudina, Sihem ;
Abel, E. Dale .
PHYSIOLOGY, 2006, 21 :250-258
[5]   Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart [J].
Burkart, Eileen M. ;
Sambandam, Nandakurnar ;
Han, Xianlin ;
Gross, Richard W. ;
Courtois, Michael ;
Gierasch, Carolyn M. ;
Shoghi, Kooresh ;
Welch, Michael J. ;
Kelly, Daniel P. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3930-3939
[6]   Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy [J].
Cheng, LH ;
Ding, GL ;
Qin, QH ;
Huang, Y ;
Lewis, W ;
He, N ;
Evans, RM ;
Schneider, MD ;
Brako, FA ;
Xiao, Y ;
Chen, YQE ;
Yang, QL .
NATURE MEDICINE, 2004, 10 (11) :1245-1250
[7]   Arachidonic acid interaction with the mitochondrial electron transport chain promotes reactive oxygen species generation [J].
Cocco, T ;
Di Paola, M ;
Papa, S ;
Lorusso, M .
FREE RADICAL BIOLOGY AND MEDICINE, 1999, 27 (1-2) :51-59
[8]   PRISM/PRDM6, a transcriptional repressor that promotes the proliferative gene program in smooth muscle cells [J].
Davis, CA ;
Haberland, M ;
Arnold, MA ;
Sutherland, LB ;
McDonald, OG ;
Richardson, JA ;
Childs, G ;
Harris, S ;
Owens, GK ;
Olson, EN .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (07) :2626-2636
[9]   Prognostic significance of left ventricular mass change during treatment of hypertension [J].
Devereux, RB ;
Wachtell, K ;
Gerdts, E ;
Boman, K ;
Nieminen, MS ;
Papademetriou, V ;
Rokkedal, J ;
Harris, K ;
Aurup, P ;
Dahlöf, B .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (19) :2350-2356
[10]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39